Novartis Sues FDA For OK'ing Generic Herpes Drug

Law360, New York (September 23, 2010, 6:03 PM EDT) -- Novartis Pharmaceuticals Corp. has accused the U.S. Food and Drug Administration of improperly granting Watson Laboratories Inc.’s abbreviated new drug application for a generic version of herpes treatment drug Famvir.

In its complaint against the FDA filed Wednesday in the U.S. District Court for the District of Columbia, Novartis said it holds sole marketing rights for Famvir until next year — an exclusivity that the company argues has been threatened by the FDA’s Sept. 14 approval of the ANDA in alleged violation of the Federal Food,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.